AI assistant
NEKTAR THERAPEUTICS — Director's Dealing 2021
Dec 21, 2021
32134_dirs_2021-12-20_62596d9f-4c9e-43f8-9489-1fefba45e953.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NEKTAR THERAPEUTICS (NKTR)
CIK: 0000906709
Period of Report: 2021-12-16
Reporting Person: Wilson Mark Andrew (SVP & General Counsel)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-12-16 | Common Stock | A | 37800 | $0.00 | Acquired | 124736 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-12-16 | Stock Option | $13.22 | A | 67150 | Acquired | 2029-12-15 | Common Stock (67150) | Direct |
Footnotes
F1: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. These RSUs vest over three years from the date of grant in substantially equal quarterly installments based on continued service.
F2: This number includes 3,607 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c).
F3: This stock option vests over four years from the date of grant in equal monthly installments based on continued service.